| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 267 | 118 | 0 | 171.509 | - |
| Total Income - EUR | - | - | - | - | - | 315 | 129 | 192 | 198.382 | - |
| Total Expenses - EUR | - | - | - | - | - | 9.549 | 11.508 | 14.791 | 303.154 | - |
| Gross Profit/Loss - EUR | - | - | - | - | - | -9.234 | -11.379 | -14.599 | -104.771 | - |
| Net Profit/Loss - EUR | - | - | - | - | - | -9.237 | -11.380 | -14.599 | -104.771 | - |
| Employees | - | - | - | - | - | 1 | 3 | 1 | 1 | - |
Check the financial reports for the company - Moogle Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 609 | 391 | 196 | 148.784 | - |
| Current Assets | - | - | - | - | - | 1.450 | 2.822 | 4.684 | 307.947 | - |
| Inventories | - | - | - | - | - | 51 | 231 | 232 | 62.685 | - |
| Receivables | - | - | - | - | - | 1.189 | 2.623 | 4.552 | 242.212 | - |
| Cash | - | - | - | - | - | 209 | -32 | -100 | 3.050 | - |
| Shareholders Funds | - | - | - | - | - | -9.195 | -20.372 | -35.033 | -139.537 | - |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 202 | - |
| Debts | - | - | - | - | - | 11.417 | 23.871 | 40.170 | 600.049 | - |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Moogle Pharma S.r.l.